Fmr LLC Boosts Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

FMR LLC grew its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 10.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,296,179 shares of the company's stock after purchasing an additional 601,611 shares during the quarter. FMR LLC owned approximately 13.33% of Enliven Therapeutics worth $160,804,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ELVN. First Turn Management LLC lifted its stake in Enliven Therapeutics by 29.5% in the third quarter. First Turn Management LLC now owns 535,092 shares of the company's stock worth $13,666,000 after acquiring an additional 121,849 shares during the period. Bank of New York Mellon Corp lifted its stake in Enliven Therapeutics by 49.2% in the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company's stock worth $2,667,000 after acquiring an additional 37,632 shares during the period. American Century Companies Inc. raised its holdings in Enliven Therapeutics by 44.7% in the second quarter. American Century Companies Inc. now owns 27,651 shares of the company's stock worth $646,000 after purchasing an additional 8,540 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in Enliven Therapeutics in the second quarter worth $322,000. Finally, SG Americas Securities LLC bought a new position in Enliven Therapeutics in the third quarter worth $256,000. Hedge funds and other institutional investors own 95.08% of the company's stock.

Insider Buying and Selling

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 37,878 shares of the firm's stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $28.16, for a total value of $1,066,644.48. Following the transaction, the insider now directly owns 1,016,035 shares of the company's stock, valued at approximately $28,611,545.60. This trade represents a 3.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 4,250 shares of the firm's stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $24.27, for a total value of $103,147.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 129,195 shares of company stock worth $3,581,772. 29.20% of the stock is owned by corporate insiders.

Enliven Therapeutics Stock Up 0.4 %

Shares of NASDAQ:ELVN traded up $0.10 on Wednesday, hitting $23.71. 118,877 shares of the company traded hands, compared to its average volume of 256,671. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $30.03. The stock has a 50 day simple moving average of $26.78 and a 200-day simple moving average of $24.14. The company has a market cap of $1.16 billion, a PE ratio of -12.48 and a beta of 1.02.

Analysts Set New Price Targets

A number of research firms have issued reports on ELVN. Robert W. Baird increased their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a report on Friday, November 15th. HC Wainwright reiterated a "buy" rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.